#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

In the for­ev­er war be­tween block­buster check­point in­hibitors, Mer­ck’s won­der drug Keytru­da has tak­en a clear edge over its near­est ri­vals in metasta­t­ic, un­re­sectable can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.